Premium
Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy
Author(s) -
Kissick Haydn T,
Ireland Demelza J,
Krishnan Shruti,
Madondo Mutsa,
Beilharz Manfred W
Publication year - 2012
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1038/icb.2012.2
Subject(s) - immunotherapy , immune system , monoclonal antibody , mesothelioma , regulator , cancer research , cytotoxic t cell , immunology , immune tolerance , antigen , medicine , cancer immunotherapy , biology , antibody , pathology , in vitro , biochemistry , gene
Numerous immunotherapy treatments for cancer are undergoing clinical trials or are already approved for use. One particular area of interest is targeting mechanisms of immune tolerance. Using a murine model of mesothelioma, we investigated the roles of regulatory T‐cells, intratumoural transforming growth factor (TGF)‐β and the negative regulator molecule cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4) in immune tolerance to tumours. It was found that treatments targeting a single negative regulator molecule mechanism were not as effective against tumours as targeting multiple mechanisms simultaneously. Most importantly, it was found that a combined triple treatment of anti‐CD25 monoclonal antibody (mAb), anti‐CTLA‐4 mAb and TGF‐β soluble receptor resulted in long‐term clearance of tumours and memory against tumour rechallenge. These data suggest that clinical application of immunotherapies against tumours may be improved by simultaneously targeting multiple mechanisms of immune suppression.